ProKidney went public via a SPAC merger with Social Capital Suvretta Holdings III in a $2.64bn deal.

ProKidney, a clinical-stage cellular therapeutics company focused on chronic kidney disease, went public via a SPAC merger with Social Capital Suvretta Holdings III, a special purpose acquisition company, in a $2.64bn deal. The transaction includes a $125m PIPE led by Social Capital. “At ProKidney, we have the potential to usher in a new era of better health for the millions of CKD patients worldwide who have few or no other options but to progress into renal failure. Based on the clinical observations of broad organ function enhancements, this therapy has the potential to have a tangible positive impact on patients’ quality of life while also providing meaningful economic benefits for the global healthcare system. We are grateful to the SCS team and our talented advisors for their support throughout this process, and excited to begin our next phase of growth and advancement as a public company," Tim Bertram, ProKidney Founder and CEO.